PARP1 and cancer: Given that the restoration of BRCA, loss of 53BP1, and even the amplification of XPC conferred resistance to PARPi in a diverse set of cancer cells, CRISPR‒CasCas9, a genome-editing technique has been exploited to establish de novo PARP inhibitor resistance [105, 148].